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A B S T R A C T
Liver resection remains one of the most technically challenging surgical procedure in abdominal surgery due to
the complex anatomical arrangement in the liver and its rich blood supply that constitutes about 20% of the
cardiac output per cycle. The challenge for resection in cirrhotic livers is even higher because of the impact of
surgical stress and trauma imposed on borderline liver function and the impaired ability for liver regeneration in
cirrhotic livers. Nonetheless, evolution and advancement in surgical techniques as well as knowledge in peri-
operative management of liver resection has led to a substantial improvement in surgical outcome in recent
decade. The objective of this article was to provide updated information on the recent developments in liver
surgery, from preoperative evaluation, to technicality of resection, future liver remnant augmentation and fi-
nally, postoperative management of complications.
1. Introduction
Liver resection remains one of the most technically challenging
surgical procedure in abdominal surgery due to the complex anatomical
arrangement in the liver and its rich blood supply that constitutes about
20% of the cardiac output per cycle. The challenge for resection in
cirrhotic livers is even higher because of the impact of surgical stress
and trauma imposed on borderline liver function and the impaired
ability for liver regeneration in cirrhotic livers. Nonetheless, evolution
and advancement in surgical techniques as well as knowledge in peri-
operative management of liver resection has led to a substantial im-
provement in surgical outcome in recent decade. The objective of this
article was to provide updated information on the recent developments
in liver surgery, from preoperative evaluation, to technicality of re-
section, future liver remnant augmentation and finally, postoperative
management of complications.
2. Preoperative liver function evaluation
Liver resection in patients with cirrhosis requires extreme care in
determining the function of the liver parenchyma (including evidence
of portal hypertension). One of the key considerations is the future liver
remnant (FLR), taking into account the amount of liver that needs to be
resected. The relationship of the lesion(s) to critical inflow pedicular
structures such as bile duct, portal vein and hepatic artery as well as
outflow structures such as hepatic veins have significant influence on
how the surgery will be performed.
The basic evaluation of functions of the liver can be performed
through simple test in Child-Pugh scoring system. In the usual guide,
Child's A patients could tolerate major liver resection provided the FLR
is sufficient, while major liver resection is generally not encouraged in
patients with Child's B and C status liver function [1,2]. In addition, if
there is evidence of portal hypertension, particularly in elevated he-
patic venous pressure, oesophageal varices, splenomegaly with throm-
bocytopenia, the risk of liver resection will also significantly increased
as this usually corresponds well to decompensated liver function [3].
The less commonly used methods of liver function scoring for total
evaluation before liver resection such as the Liver damage grade and
the model for end-stage liver disease (MELD) score are also reported in
the literature [4–8]. Liver damage grading proposed by the Liver
Cancer Study Group of Japanese has 5 components including degree of
ascites, serum albumin and bilirubin levels, ICG-R15% as well as pro-
thrombin activity. Recently, an international study group proposed the
use of ALBI grading system to further enhance the ability to dis-
criminate patients with HCC who will benefit from resection versus
other treatments. It is reported to be better than the existing grading
system such as Child-Pugh score in selecting therapeutic options for
HCC patients [9,10].
Further evaluation of the quality and function of the hepatocytes
can be achieved by performing the Indocyanine Green (ICG) Clearance
test [11]. The ICG dye is exclusively cleared by the hepatocytes and
excreted into the biliary system, the amount of ICG retained in the
blood at a certain duration after injection can be used to stratify the risk
of major liver resection. Imamura et al. proposed the use of Makuuchi
decisional algorithm using ICG retention at 15 minutes as follows [12]:
❖ <10% at 15min for trisectionectomy or bisectorectomy of liver
❖ 10–19% for hemihepatectomy, right sided sectorectomy
❖ 20–29% for segmentectomy
❖ 30–39% for limited resection (eg wedge resection)
❖ >40% for enucleation
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In recent years, liver scintigraphy has also been adopted into the
algorithm to evaluate the liver function and volume and it has been
validated as a tool to assess the total liver function and functional
remnant liver before liver surgery. 99mTc-labeled diethylene-
triaminepentaacetic acid galactosyl human serum albumin (GSA) scin-
tigraphy and hepatobiliary scintigraphy (HBS) with 99m Tc-labeled
iminodiacetic acid (IDA) derivatives are some of the scintigraphic liver
function tests available commercially. Both of them can provide
quantitative and visual information on total and regional hepatic
function. 99 m Tc-GSA SPECT-CT has been used in monitoring FRL after
PVE where more pronounced increase in FRL function after PVE was
observed compared to the volumetric increase measured with CT vo-
lumetry [13,14]. It has also been used to monitor the liver regeneration
after hepatic resection in some cases [15].
99m Tc-mebrofenin is the most liver-specific Tc-IDA derivative. The
99 m Tc-mebrofenin circulates in an albumin-bound form and dis-
sociates from albumin after uptake into hepatocytes through organic
anion transporters. 99 m Tc-mebrofenin undergoes biliary excretion
without undergoing biotransformation, similar to ICG. Therefore, the
mebrofenin hepatic uptake can be calculated in the same way as for
ICG. This uptake rate strongly correlates with the ICG clearance test
[16]. Preoperatively measured FRL function with 99 m Tc-mebrofenin
HBS has been proven to correlate with postoperative FLR function on
postoperative day 1 [17]. In patients with normal liver parenchyma
undergoing partial liver resection, preoperative measurement of 99 m
Tc-mebrofenin uptake by the FRL was more accurate in predicting
postoperative liver insufficiency and liver insufficiency-related mor-
tality than preoperative measurement of FRL volume [18]. [bib18].
Based on a consensus statement in 2010, the Vauthey report [19]
stated that the minimum liver volume required after liver resection was
estimated to be approximately 20% for a normal liver, 30% for an in-
jured liver and 40% for a liver with well-compensated hepatic fibrosis
and cirrhosis. Furthermore, the Hong Kong team has further proposed
using CT volumetric to enhance safety measures of patients who show
an ICGR 15 of 14–20% [20]. In patients with borderline liver function
reserve for major hepatectomy, roughly 30–40% can be considered safe
remnant liver volume.
3. Open liver resection: tips and tricks
During the last two decades, relevant improvements have rendered
even extended liver resections in higher-degree cirrhotic patients with
portal hypertension possible. However, there are few standard indica-
tions for hepatic resections in cirrhotic patients and risk stratifications
have to be performed in an interdisciplinary setting for each individual
patient [21–23]. The CTP score and Model for End-stage Liver Disease
(MELD) can be used to assess the perioperative risk. On the other hand,
hepatic resections in cirrhotic patients with portal hypertension show a
significantly increased mortality and morbidity. However, surgery is
feasible in selected patients with adequate long-term outcome [24]. The
recanalized umbilical vein must be preserved if possible if not carefully
ligated and it is important point in patients with portal hypertension. To
preserve it, we can use J-shape, easier than subcostal laparotomy and
the collateral circulations is less affected. Depending on the tumor lo-
calization we could conserve the liver ligaments for the same reasons.
The most frequent indication for hepatic resections in cirrhotic pa-
tients with and without portal hypertension is HCC. Despite the ad-
vances, only 15%–30% of patients with HCC are candidates to resection
[4]. As anforementioned, in selected case the portal hypertension
should not be a contraindication, several authors have demonstrated
that 5-year overall survival as high as e 68% in selected patients al-
though the type of resection tends to be limited to less two segments.
The degree of portal hypertension becomes another important clinical
factor that influences the size and scope of possible resection.
In cirrhotic liver, a minimum of 40% well-perfused liver remnants in
the patients after hepatic resection. Normally, these radical resections
are offered to CPT A, MELD<9 with no or only mild portal hy-
pertension. It would be preferred hepatic resections to be as par-
enchymal-sparing as possible. In contrast, the latter strategy may en-
able liver resections in patients with advanced cirrhosis (CPT B) and
with mild portal hypertension [25] Parenchymal-sparing resections via
open approach would be more safer, although there has been con-
flicting data to suggest that both disease-free and overall survival were
better with anatomical resection when compared with non-anatomical
resections [26–28].
Blood loss and blood transfusions have been defined as independent
predictors of postoperative morbidity and mortality. During par-
enchymal dissection with high blood loss, hilar vascular occlusion can
be applied (Pringle maneuver [29]). Although, the Pringle maneuver is
not recommended in cirrhotic patients but sometimes to avoid ex-
tensive blood loss, it should still be considered as exsanguinating hae-
morrhage would inevitably lead to shock, and subsequently liver failure
[30]. If vascular clamping cannot be avoided, selective clamping of a
hepatic lobe, section or segment is recommended to limit ischemic and
if longer occlusion is needed, intermittent occlusion, e.g., intervals of
15 min of ischemia and 5 min to reperfusion is preferred over con-
tinuous clamping [31]. The liver hanging maneuver facilitates anterior
approach of major hepatectomy and minimizes bleeding by elevation of
the liver along its deeper parenchymal plane [32]. In case of substantial
bleeding from the transection surface, total vascular exclusion is an-
other effective approach to allow examination of the bleeding points
and haemostasis. For large bulky tumors, open approach remained the
mainstay of treatment but it may become safe and feasible via mini-
mally invasive approach as techniques and experience is advancing.
Drainage placement is not recommended because increasing the septic
complications, impair the ascites management and prolongation of the
length of hospital stay.
4. Minimally invasive surgery for liver resections
The advantages of minimally invasive liver surgery compared to the
classic “open” approach are well known and may result in easier access
to the abdomen in cases of future liver transplantation (LT) [33,34].
Moreover, it provides favorable perioperative outcomes including sig-
nificantly less intraoperative blood loss, shorter hospital stay, and less
postoperative morbidity, without affecting the oncological result [35].
Several studies have demonstrated that minimally invasive liver re-
section is safe, feasible, and particularly effective for parenchyma-
sparing procedures, such as those needed in patients with cirrhosis.
Advantages of a minimally invasive approach are in fact both surgical
and medical, thanks to the reduced surgical trauma and the small im-
pact on fluid management and patient mobilization [36,37]. There are
also technical advantages of the robotic platform that make for a more
comfortable approach for the surgeon, even to complex procedures that
classically requires an extremely skilled laparoscopic surgeon. For ex-
ample, the TilePro function on the robotic console is an important re-
source of the robotic platform that displays at the same time the clas-
sical endoscopic view and imaging sources such as the US, CT scan, MR
images. This represents a valuable improvement compared to standard
laparoscopy since the operating surgeon no longer needs to switch from
a screen to another to visualize the intra-operative US.
Indocyanine green (ICG) fluorescence is an additional tool to per-
form guided liver resections, that may be particularly helpful to obtain
parenchymal resections respecting the anatomic paradigm [38]. How-
ever, the ability of ICG fluorescence to identify HCC nodules may be
affected by the presence of cirrhosis and varies according to tumor
depth [39,40]. Given the low positive predictive value of this proce-
dure, detection of HCC nodules with ICG fluorescence in cirrhotic pa-
tients seems not reliable so far.
Furthermore, it has recently been shown that patients with clinically
significant portal hypertension (CSPH) may benefit from a minimally
invasive approach instead of an open one. In detail, a study from Spain
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comparing 30 patients with HCC and no-CSPH versus 15 patients with
HCC and CSPH, demonstrated that the two groups have the same in-
cidence of peri-operative morbidity, and no differences in terms of
disease-free and overall survival [41]. Those data were later confirmed
from another study including patients undergone minor and major la-
paroscopic and robotic liver resections and comparing CSPH versus no-
CSPH ([18and27], respectively) [42]. Those data confirm that indica-
tions for minimally invasive liver surgery can be pushed in experienced
centers and after a specific learning curve, to guarantee oncological
outcomes and patient safety.
5. Future liver remnant augmentation: portal vein embolization
versus ALPPS procedure
After the introduction of portal vein embolization (PVE) by
Makuuchi et al., in 1990 [43], several Asian centers advocated its safety
and feasibility in cirrhotic patients with hepatocellular carcinoma
(HCC), and the increased volume of the future liver remnant (FLR) by
PVE was approximately 30%–40% [44,45]. A meta-analysis on PVE for
major liver resection demonstrated that percutaneous transhepatic ap-
proach produces greater increase in FLR volume than transileocolic
approach via minilaparotomy [46] The access route to the portal
system can either be ipsilateral (through the tumor-bearing liver) with
retrograde embolization, or contralateral (through FLR) with antegrade
embolization. Comparisons between these two methods have shown
equivalent safety and efficacy [47]. Azoulay et al. were the first to re-
port comparable long-term outcomes after major liver resection for
HCC in injured liver with (n = 9) and without PVE (n = 19) [48]. They
systematically performed PVE for patients needing major hepatectomy
when FLR was ≤40% and described a significant increase in FLR (gain,
46 ± 24%; p < 0.0001). None of the patients suffered post-hepa-
tectomy liver failure. A systematic review concluded that patients with
preexisting liver damage due to cirrhosis demonstrated less hyper-
trophy response to PVE compared to normal liver [49]. More recently,
Sun et al. reported no significant difference in FLR enlargement 4–6
weeks after PVE between cirrhotic (n = 12) and non-cirrhotic (n = 9)
patients undergoing right hepatectomy for primary liver cancer (HCC,
17; intrahepatic cholangiocarcinoma, 4) [50].
Associating liver partition and portal vein ligation for staged he-
patectomy (ALPPS) [51] is gaining momentum as an alternative for
liver augmentation for the higher degree and more rapid enlargement
of FLR than PVE. The high short-term morbidity and mortality rates
reported in the early series have considerably improved over the years
due to the establishment of the international ALPPS registry (http://
www.alpps.net/?q=registry) and technical refinements [52]. However,
D'Hasse et al. reported an unacceptably high 90-day mortality of 31% in
patients who underwent ALLPS for HCC (n = 35), which was almost
fivefold higher than that for colorectal liver metastases (n = 225; 90-
day mortality, 7%, p < 0.001) based on the aforementioned registry
data. They concluded that ALPPS for HCC should only be employed in
highly selected patients< 60 years of age with low-grade fibrosis [53].
Other centers reported varying results of ALPPS for HCC in cirrhotic
patients: although the increase of FLR was adequate ranging from 50%
to> 70% in a median of seven to 14 days, the mortality rate still ex-
ceeded 10% [54–56]. More recently, Chan et al. reported a landmark
study comparing ALLPS (n = 45) vs. PVE (n = 69) for HCC [57]. This
was one of the largest series describing the effect of liver augmentation
in a cirrhotic liver [65/114 (57%) patients who underwent resection
had cirrhosis]. ALPPS increased FLR by 48.8% over six days and pro-
vided higher resectability rate compared with PVE (97.7% vs. 67.7%,
p < 0.001). The hospital mortality was 6.5%, equivalent to that of PVE
(5.8%, p = 1.00). It is noteworthy that no significant difference was
observed in 5-year overall survival (ALPPS, 46.8% vs. PVE, 64.1%;
p = 0.23), regardless of tumor stage and without obvious discrepancy
in the pattern of disease recurrence. They proposed that ALPPS should
be reserved for patients with FLR/estimated standard liver volume<
30% and PVE for FLR/estimated standard liver volume 30%–40%, with
exception for tumors with marcovascular invasion requiring more rapid
regeneration. They also mentioned that a longer interval of two weeks
or more is required between the ALPPS procedure and stage II hepa-
tectomy in patients with a cirrhotic liver or those with intraoperative
indocyanine green value > 39.5%, Based on the evidence available to
date, there are pros and cons of PVE and ALPPS and both techniques are
considered to play complementary roles in improving resectability of
primary liver cancer in cirrhotic patients. Evidence remain scarce re-
garding the effect of liver augmentation on tumor microenvironment
and well-designed, prospective studies are warranted to establish in-
dications of PVE and ALPPS.
Besides conventional PVE and ALPPS, other innovative techniques
have been introduced for further augmentation of FLR in cirrhotic pa-
tients.
i. The use of sequential transarterial embolization (TAE) + PVE for a
cirrhotic liver has been advocated by several centers [58–61]. All
reported significantly improved disease-free survival; however,
whether TAE + PVE induces significantly higher increase in FLR
size than PVE alone remains inconclusive [58,60,61].
ii. Yttrium-90 (90Y) radioembolization is another alternative for PVE.
Four centers have reported 90Y radioembolization followed by
major hepatectomy in more than 40 patients with cirrhosis, mostly
for HCC [62–65]. Although a wide variety exists in the emboliza-
tion agent, radiation dose, and number of sessions, the procedure is
well tolerated with promising oncological outcomes. A systematic
review described a significantly higher degree of FLR increase with
PVE compared with 90Y radioembolization within a shorter time
interval, but this study included both normal and cirrhotic livers
[66]. The definitive role of this emerging therapy with special re-
ference to the kinetic growth rate, adverse events, and long-term
prognoses needs further evaluation [67].
ii. Sequential right hepatic vein embolization in cirrhotic patients who
showed limited FLR hypertrophy after PVE awaiting right hepa-
tectomy safely and effectively facilitated liver regeneration, al-
though the rate of enlargement was lower compared with that of
non-cirrhotic patients [68]. Guiu et al. conducted simultaneous
PVE and embolization of the right and middle hepatic veins (ex-
tended liver venous deprivation) in non-cirrhotic patients with
marked and rapid increase in FLR function and volume [69]. The
same team stated that while the increase in FLR volume with this
technique is comparable to ALPPS, the FLR functional increase
measured by 99mTc-mebrofenin hepatobiliary scintigraphy is sub-
stantially better than ALPPS [70]; however, whether these findings
are applicable to cirrhotic patients remains unknown.
iv. A recent meta-analysis on the protective role of ischemic pre-
conditioning before the Pringle maneuver (hepatic inflow occlu-
sion) during liver resection concluded that ischemic pre-
conditioning may be beneficial for cirrhotic patients by
significantly reducing postoperative morbidity compared with the
control group, based on six randomized control trials that enrolled
both cirrhotic and noncirrhotic patients [71].
v. Splenectomy in cirrhotic patients with hypersplenism has been re-
ported to alleviate liver function, improve immunological response,
and reduce HCC recurrence [72–74]. A meta-analysis concluded
that simultaneous splenectomy and hepatectomy for HCC compli-
cated with hypersplenism increase postoperative white blood cell
and platelet counts, ameliorates liver function, and improves dis-
ease-free and overall survival rates; however, all pooled studies
were retrospective and observational [75].
vi. In situ hypothermic liver perfusion during liver resection is con-
sidered beneficial to reduce ischemic-reperfusion injury; however,
there is only one randomized control study that prospectively
compared this technique with the gold standard intermittent
Pringle maneuver in patients without underlying liver disease
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undergoing right (extended) hepatectomy [76]. Whether it can be
safely and effectively applied in cirrhotic patients warrants further
investigation.
vii. Two-stage hepatectomy with portal vein ligation has been widely
accepted for noncirrhotic patients with multiple bilobar colorectal
metastases and yields satisfactory short- and long-term outcomes
[77]. Its indication in cirrhotic livers has yet to be defined.
5.1. Postoperative management and management of complications
Attentive postoperative management forms a core element in en-
suring an uneventful and speedy recovery after major hepatectomy,
especially in cirrhotic livers. A tight fluid balance should be maintained
throughout the perioperative phase [78]. Supplementary intravenous
albumin infusion in the first few postoperative days helped to maintain
adequate oncotic pressure in the intravascular compartment and urine
output. Opioids should be avoided for pain control due to the risk of
paralytic ileus and non-steroidal anti-inflammatory agents is preferred.
Early postoperative oral nutrition that promoted liver regeneration
should commence as soon as possible and could be supplemented by
branched chained amino acids [79]. An enhanced recovery program
has been shown to hasten recovery and shorten hospital stay [80–82].
Active spirometry exercise should be practiced to reduce the chance of
atelectasis or pneumonia.
Vigilance for subtle abnormal clinical signs such as borderline ta-
chycardia, pyrexia, oliguria or prolonged ileus facilitated early detec-
tion of postoperative complications that remained crucial to avoid
fatality. Exploratory laparotomy is indicated if there are clinical signs
suspicious of haemorrhage [83]. In case of portal vein thrombosis,
emergency thrombectomy via operative approach [84] or radiological
approach with thrombolysis [85,86] were both effective measures. For
postoperative biliary leakage, endoscopic retrograde cholangiopan-
creatography with stenting allows early detection and timely inter-
vention to seal off the leakage [87–89]. For large volume (i.e. >
200ml/day) of biliary leakage, early operative repair was still preferred
due to the risk of antibiotic resistant biliary sepsis caused by prolonged
biliary fistula.
One of the most dreadful complications, for both surgeons and pa-
tients, was post-hepatectomy liver failure (PHLF) that was frequently
associated with mortality. A substantial reduction of liver mass after
major hepatectomy gave rise to a phenomenon in analogy with ‘small
for size syndrome’ in living-related liver transplantation [90]. The in-
creased portal flow and pressure to the small remnant liver after he-
patectomy caused significant hepatocyte damage owing to the in-
creased sinusoidal stress [90]. PHLF could be classified into three
grades according to the recommendations by the International Study
Group of Liver Surgery (ISGLS) [91] while serum platelet counts and
the albumin-bilirubin (ALBI) score provided good predictive value for
PHLF [92–94]. With regard to management, Grade A PHLF usually
resolved on conservative management while a more aggressive treat-
ment approach for grade B PHLF in the form of fresh-frozen plasma,
albumin infusion, diuretics and branch-chained amino acids supple-
mentation were indicated. Postoperative somatostatin infusion to re-
duce the portal pressure should also be considered providing the portal
pressure was>20mHg [95]. On the other hand, the evidence to sup-
port the use of molecular adsorbent recirculating system (MARS) was
still lacking [95]. For grade C PHLF, a timely referral for liver trans-
plantation before occurrence of septicaemia should be considered in
order to improve the outlook of the patient [96].
6. Conclusion
A detailed preoperative evaluation, choosing the appropriate op-
erative approach and surgical maneuver to minimize intraoperative
bleeding, followed by attentive postoperative management form the
cornerstones for a safe liver resection in cirrhotic livers.
Data statement





Research registration Unique Identifying number (UIN)
1. Name of the registry:
2. Unique Identifying number or registration ID:
3. Hyperlink to your specific registration (must be publicly accessible
and will be checked):
Guarantor
Albert Chan.
CRediT authorship contribution statement
Albert Chan: Conceptualization, Data curation, Formal analysis,
Project administration, Writing - original draft. Alfred Kow: Formal
analysis, Data curation, Writing - original draft, Writing - review &
editing. Taizo Hibi: Formal analysis, Data curation, Writing - original
draft, Writing - review & editing. Fabrizio Di Benedetto: Formal
analysis, Data curation, Writing - original draft, Writing - review &
editing. Alejandro Serrablo: Formal analysis, Data curation, Writing -
original draft, Writing - review & editing.
Declaration of competing interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
References
[1] C.G. Child, J.G. Turcotte, Surgery and portal hypertension, Major Probl. Clin. Surg.
1 (1964) 1–85.
[2] R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, R. Williams, Transection
of the oesophagus for bleeding oesophageal varices, Br. J. Surg. 60 (8) (1973)
646–649.
[3] T. Mizuguchi, M. Kawamoto, M. Meguro, T.T. Hui, K. Hirata, Preoperative liver
function assessments to estimate the prognosis and safety of liver resections, Surg.
Today 44 (1) (2014) 1–10.
[4] J.N. Vauthey, A. Chaoui, K.A. Do, M.M. Bilimoria, M.J. Fenstermacher,
C. Charnsangavej, et al., Standardized measurement of the future liver remnant
prior to extended liver resection: methodology and clinical associations, Surgery
127 (5) (2000) 512–519.
[5] L.T. Hoekstra, W. de Graaf, G.A. Nibourg, M. Heger, R.J. Bennink, B. Stieger, et al.,
Physiological and biochemical basis of clinical liver function tests: a review, Ann.
Surg. 257 (1) (2013) 27–36.
[6] K. Omagari, K. Ohba, Y. Kadokawa, H. Hazama, J. Masuda, H. Kinoshita, et al.,
Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group
of Japan and Child-Pugh classification in patients with hepatocellular carcinoma,
Hepatol. Res. 34 (4) (2006) 266–272.
[7] T.I. Huo, S.D. Lee, H.C. Lin, Selecting an optimal prognostic system for liver cir-
rhosis: the model for end-stage liver disease and beyond, Liver Int. 28 (5) (2008)
606–613.
[8] E. Cholongitas, L. Marelli, V. Shusang, M. Senzolo, K. Rolles, D. Patch, et al., A
systematic review of the performance of the model for end-stage liver disease
(MELD) in the setting of liver transplantation, Liver Transplant. 12 (7) (2006)
1049–1061.
[9] A. Hiraoka, T. Kumada, K. Michitaka, M. Kudo, Newly proposed ALBI grade and
ALBI-T score as tools for assessment of hepatic function and prognosis in hepato-
cellular carcinoma patients, Liver Cancer 8 (5) (2019) 312–325.
[10] P.J. Johnson, S. Berhane, C. Kagebayashi, S. Satomura, M. Teng, H.L. Reeves, et al.,
Perspective International Journal of Surgery xxx (xxxx) xxx–xxx
4
Assessment of liver function in patients with hepatocellular carcinoma: a new
evidence-based approach-the ALBI grade, J. Clin. Oncol. 33 (6) (2015) 550–558.
[11] T.I. Huo, H.C. Lin, S.C. Huo, P.C. Lee, J.C. Wu, F.Y. Lee, et al., Comparison of four
model for end-stage liver disease-based prognostic systems for cirrhosis, Liver
Transplant. 14 (6) (2008) 837–844.
[12] H. Imamura, K. Sano, Y. Sugawara, N. Kokudo, M. Makuuchi, Assessment of hepatic
reserve for indication of hepatic resection: decision tree incorporating indocyanine
green test, J Hepatobiliary Pancreat Surg 12 (1) (2005) 16–22.
[13] I. Hirai, W. Kimura, A. Fuse, K. Suto, M. Urayama, Evaluation of preoperative portal
embolization for safe hepatectomy, with special reference to assessment of none-
mbolized lobe function with 99mTc-GSA SPECT scintigraphy, Surgery 133 (5)
(2003) 495–506.
[14] Y. Nishiyama, Y. Yamamoto, I. Hino, K. Satoh, H. Wakabayashi, M. Ohkawa, 99mTc
galactosyl human serum albumin liver dynamic SPET for pre-operative assessment
of hepatectomy in relation to percutaneous transhepatic portal embolization, Nucl.
Med. Commun. 24 (7) (2003) 809–817.
[15] A.H. Kwon, Y. Matsui, S.K. Ha-Kawa, Y. Kamiyama, Functional hepatic volume
measured by technetium-99m-galactosyl-human serum albumin liver scintigraphy:
comparison between hepatocyte volume and liver volume by computed tomo-
graphy, Am. J. Gastroenterol. 96 (2) (2001) 541–546.
[16] D. Erdogan, B.H. Heijnen, R.J. Bennink, M. Kok, S. Dinant, I.H. Straatsburg, et al.,
Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin
scintigraphy with indocyanine green clearance test, Liver Int. 24 (2) (2004)
117–123.
[17] R.J. Bennink, S. Dinant, D. Erdogan, B.H. Heijnen, I.H. Straatsburg, A.K. van Vliet,
et al., Preoperative assessment of postoperative remnant liver function using he-
patobiliary scintigraphy, J. Nucl. Med. 45 (6) (2004) 965–971.
[18] S. Dinant, W. de Graaf, B.J. Verwer, R.J. Bennink, K.P. van Lienden, D.J. Gouma,
et al., Risk assessment of posthepatectomy liver failure using hepatobiliary scinti-
graphy and CT volumetry, J. Nucl. Med. 48 (5) (2007) 685–692.
[19] J.N. Vauthey, E. Dixon, E.K. Abdalla, W.S. Helton, T.M. Pawlik, B. Taouli, et al.,
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement,
HPB 12 (5) (2010) 289–299.
[20] R.T. Poon, S.T. Fan, Hepatectomy for hepatocellular carcinoma: patient selection
and postoperative outcome, Liver Transplant. 10 (2 Suppl 1) (2004) S39–S45.
[21] T. Ishizawa, K. Hasegawa, T. Aoki, M. Takahashi, Y. Inoue, K. Sano, et al., Neither
multiple tumors nor portal hypertension are surgical contraindications for hepa-
tocellular carcinoma, Gastroenterology 134 (7) (2008) 1908–1916.
[22] J.H. Zhong, Y. Ke, W.F. Gong, B.D. Xiang, L. Ma, X.P. Ye, et al., Hepatic resection
associated with good survival for selected patients with intermediate and advanced-
stage hepatocellular carcinoma, Ann. Surg. 260 (2) (2014) 329–340.
[23] A. Cucchetti, G. Ercolani, M. Vivarelli, M. Cescon, M. Ravaioli, G. Ramacciato, et al.,
Is portal hypertension a contraindication to hepatic resection? Ann. Surg. 250 (6)
(2009) 922–928.
[24] Y. Fong, R.L. Sun, W. Jarnagin, L.H. Blumgart, An analysis of 412 cases of hepa-
tocellular carcinoma at a Western center, Ann. Surg. 229 (6) (1999) 790–799 dis-
cussion 9-800.
[25] Y. Tomimaru, H. Eguchi, S. Marubashi, H. Wada, S. Kobayashi, M. Tanemura, et al.,
Equivalent outcomes after anatomical and non-anatomical resection of small he-
patocellular carcinoma in patients with preserved liver function, Dig. Dis. Sci. 57
(7) (2012) 1942–1948.
[26] A. Cucchetti, M. Cescon, G. Ercolani, E. Bigonzi, G. Torzilli, A.D. Pinna, A com-
prehensive meta-regression analysis on outcome of anatomic resection versus
nonanatomic resection for hepatocellular carcinoma, Ann. Surg Oncol. 19 (12)
(2012) 3697–3705.
[27] A. Cucchetti, G.L. Qiao, M. Cescon, J. Li, Y. Xia, G. Ercolani, et al., Anatomic versus
nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma,
Surgery 155 (3) (2014) 512–521.
[28] Y. Zhou, D. Xu, L. Wu, B. Li, Meta-analysis of anatomic resection versus non-
anatomic resection for hepatocellular carcinoma, Langenbeck's Arch. Surg. 396 (7)
(2011) 1109–1117.
[29] S. Famularo, A. Giani, S. Di Sandro, M. Sandini, A. Giacomoni, E. Pinotti, et al.,
Does the Pringle maneuver affect survival and recurrence following surgical re-
section for hepatocellular carcinoma? A western series of 441 patients, J. Surg.
Oncol. 117 (2) (2018) 198–206.
[30] D. Citterio, A. Facciorusso, C. Sposito, R. Rota, S. Bhoori, V. Mazzaferro, Hierarchic
interaction of factors associated with liver decompensation after resection for he-
patocellular carcinoma, JAMA Surg 151 (9) (2016) 846–853.
[31] N. Lin, J. Li, Q. Ke, F. Xin, Y. Zeng, L. Wang, et al., Does the intermittent Pringle
maneuver affect the recurrence following surgical resection for hepatocellular
carcinoma? A systematic review, PloS One 15 (3) (2020) e0229870.
[32] T. Beppu, K. Imai, K. Okuda, S. Eguchi, K. Kitahara, N. Taniai, et al., Anterior ap-
proach for right hepatectomy with hanging maneuver for hepatocellular carcinoma:
a multi-institutional propensity score-matching study, J. Hepatobil. Pancreat. Sci.
24 (3) (2017) 127–136.
[33] R. Memeo, N. de'Angelis, V. de Blasi, Z. Cherkaoui, O. Brunetti, V. Longo, et al.,
Innovative surgical approaches for hepatocellular carcinoma, World J. Hepatol. 8
(13) (2016) 591–596.
[34] P. Magistri, T. Olivieri, G. Assirati, G.P. Guerrini, R. Ballarin, G. Tarantino, et al.,
Robotic liver resection expands the opportunities of bridging before liver trans-
plantation, Liver Transplant. 25 (7) (2019) 1110–1112.
[35] D.H. Han, S.H. Choi, E.J. Park, D.R. Kang, G.H. Choi, J.S. Choi, Surgical outcomes
after laparoscopic or robotic liver resection in hepatocellular carcinoma: a pro-
pensity-score matched analysis with conventional open liver resection, Int J Med.
Robot 12 (4) (2016) 735–742.
[36] P. Magistri, G. Tarantino, R. Ballarin, A. Coratti, F. Di Benedetto, Robotic liver
surgery is the optimal approach as bridge to transplantation, World J. Hepatol. 9 (4)
(2017) 224–226.
[37] R. Costi, O. Scatton, L. Haddad, B. Randone, W. Andraus, P.P. Massault, et al.,
Lessons learned from the first 100 laparoscopic liver resections: not delaying con-
version may allow reduced blood loss and operative time, J. Laparoendosc. Adv.
Surg. Tech. 22 (5) (2012) 425–431.
[38] G. Berardi, G. Wakabayashi, K. Igarashi, T. Ozaki, N. Toyota, A. Tsuchiya, et al., Full
laparoscopic anatomical segment 8 resection for hepatocellular carcinoma using the
glissonian approach with indocyanine green dye fluorescence, Ann. Surg Oncol. 26
(8) (2019) 2577–2578.
[39] T. Tanaka, M. Takatsuki, M. Hidaka, T. Hara, I. Muraoka, A. Soyama, et al., Is a
fluorescence navigation system with indocyanine green effective enough to detect
liver malignancies? J Hepatobiliary Pancreat Sci 21 (3) (2014) 199–204.
[40] H.J. Lim, A.K.H. Chiow, L.S. Lee, S.S. Tan, B.K. Goh, Y.X. Koh, et al., Novel method
of intraoperative liver tumour localisation with indocyanine green and near-in-
frared imaging, Singap. Med. J. Nov 2019 (2019), https://doi.org/10.11622/smedj.
2019137.
[41] V. Molina, J. Sampson-Davila, J. Ferrer, C. Fondevila, R. Diaz Del Gobbo,
D. Calatayud, et al., Benefits of laparoscopic liver resection in patients with hepa-
tocellular carcinoma and portal hypertension: a case-matched study, Surg. Endosc.
32 (5) (2018) 2345–2354, https://doi.org/10.1007/s00464-017-5930-1.
[42] C. Lim, M. Osseis, E. Lahat, A. Doussot, D. Sotirov, F. Hemery, et al., Safety of
laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal
hypertension: interim analysis of an open prospective study, Surg. Endosc. 33 (3)
(2019) 811–820.
[43] M. Makuuchi, B.L. Thai, K. Takayasu, T. Takayama, T. Kosuge, P. Gunven, et al.,
Preoperative portal embolization to increase safety of major hepatectomy for hilar
bile duct carcinoma: a preliminary report, Surgery 107 (5) (1990) 521–527.
[44] K. Yamakado, K. Takeda, K. Matsumura, A. Nakatsuka, T. Hirano, N. Kato, et al.,
Regeneration of the un-embolized liver parenchyma following portal vein emboli-
zation, J. Hepatol. 27 (5) (1997) 871–880.
[45] H. Wakabayashi, S. Okada, T. Maeba, H. Maeta, Effect of preoperative portal vein
embolization on major hepatectomy for advanced-stage hepatocellular carcinomas
in injured livers: a preliminary report, Surg. Today 27 (5) (1997) 403–410.
[46] A. Abulkhir, P. Limongelli, A.J. Healey, O. Damrah, P. Tait, J. Jackson, et al.,
Preoperative portal vein embolization for major liver resection: a meta-analysis,
Ann. Surg. 247 (1) (2008) 49–57.
[47] A.S. Khan, S. Garcia-Aroz, M.A. Ansari, S.M. Atiq, M. Senter-Zapata, K. Fowler,
et al., Assessment and optimization of liver volume before major hepatic resection:
current guidelines and a narrative review, Int. J. Surg. 52 (2018) 74–81.
[48] D. Azoulay, D. Castaing, J. Krissat, A. Smail, G.M. Hargreaves, A. Lemoine, et al.,
Percutaneous portal vein embolization increases the feasibility and safety of major
liver resection for hepatocellular carcinoma in injured liver, Ann. Surg. 232 (5)
(2000) 665–672.
[49] K.P. van Lienden, J.W. van den Esschert, W. de Graaf, S. Bipat, J.S. Lameris,
T.M. van Gulik, et al., Portal vein embolization before liver resection: a systematic
review, Cardiovasc. Intervent. Radiol. 36 (1) (2013) 25–34.
[50] J.H. Sun, Y.L. Zhang, C.H. Nie, J. Li, T.Y. Zhou, G.H. Zhou, et al., Effects of liver
cirrhosis on portal vein embolization prior to right hepatectomy in patients with
primary liver cancer, Oncol Lett 15 (2) (2018) 1411–1416.
[51] A.A. Schnitzbauer, S.A. Lang, H. Goessmann, S. Nadalin, J. Baumgart, S.A. Farkas,
et al., Right portal vein ligation combined with in situ splitting induces rapid left
lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in
small-for-size settings, Ann. Surg. 255 (3) (2012) 405–414.
[52] V. Lopez-Lopez, R. Robles-Campos, R. Brusadin, A. Lopez-Conesa, J. de la Pena,
A. Caballero, et al., ALPPS for hepatocarcinoma under cirrhosis: a feasible alter-
native to portal vein embolization, Ann. Transl. Med. 7 (22) (2019) 691.
[53] J.G. D'Haese, J. Neumann, M. Weniger, S. Pratschke, B. Bjornsson, V. Ardiles, et al.,
Should ALPPS be used for liver resection in intermediate-stage HCC? Ann. Surg
Oncol. 23 (4) (2016) 1335–1343.
[54] G. Vennarecci, G.L. Grazi, I. Sperduti, E. Busi Rizzi, E. Felli, M. Antonini, et al.,
ALPPS for primary and secondary liver tumors, Int. J. Surg. 30 (2016) 38–44.
[55] M. Serenari, M. Zanello, E. Schadde, E. Toschi, F. Ratti, E. Gringeri, et al.,
Importance of primary indication and liver function between stages: results of a
multicenter Italian audit of ALPPS 2012-2014, HPB 18 (5) (2016) 419–427.
[56] Q. Wang, J. Yan, X. Feng, G. Chen, F. Xia, X. Li, et al., Safety and efficacy of
radiofrequency-assisted ALPPS (RALPPS) in patients with cirrhosis-related hepa-
tocellular carcinoma, Int. J. Hyperther. 33 (7) (2017) 846–852.
[57] A. Chan, W.Y. Zhang, K. Chok, J. Dai, R. Ji, C. Kwan, et al., ALPPS versus portal vein
embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm
in modulation of future liver remnant before major hepatectomy, Ann. Surg. (Jul
10) (2019), https://doi.org/10.1097/SLA.0000000000003433.
[58] S. Ogata, J. Belghiti, O. Farges, D. Varma, A. Sibert, V. Vilgrain, Sequential arterial
and portal vein embolizations before right hepatectomy in patients with cirrhosis
and hepatocellular carcinoma, Br. J. Surg. 93 (9) (2006) 1091–1098.
[59] H. Imamura, Y. Seyama, M. Makuuchi, N. Kokudo, Sequential transcatheter arterial
chemoembolization and portal vein embolization for hepatocellular carcinoma: the
university of Tokyo experience, Semin. Intervent. Radiol. 25 (2) (2008) 146–154.
[60] P.D. Peng, O. Hyder, M. Bloomston, H. Marques, C. Corona-Villalobos, E. Dixon,
et al., Sequential intra-arterial therapy and portal vein embolization is feasible and
safe in patients with advanced hepatic malignancies, HPB 14 (8) (2012) 523–531.
[61] H. Yoo, J.H. Kim, G.Y. Ko, K.W. Kim, D.I. Gwon, S.G. Lee, et al., Sequential
transcatheter arterial chemoembolization and portal vein embolization versus
portal vein embolization only before major hepatectomy for patients with hepato-
cellular carcinoma, Ann. Surg Oncol. 18 (5) (2011) 1251–1257.
[62] M. Vouche, R.J. Lewandowski, R. Atassi, K. Memon, V.L. Gates, R.K. Ryu, et al.,
Perspective International Journal of Surgery xxx (xxxx) xxx–xxx
5
Radiation lobectomy: time-dependent analysis of future liver remnant volume in
unresectable liver cancer as a bridge to resection, J. Hepatol. 59 (5) (2013)
1029–1036.
[63] N. Fernandez-Ros, N. Silva, J.I. Bilbao, M. Inarrairaegui, A. Benito, D. D'Avola,
et al., Partial liver volume radioembolization induces hypertrophy in the spared
hemiliver and no major signs of portal hypertension, HPB 16 (3) (2014) 243–249.
[64] J. Goebel, M. Sulke, A. Lazik-Palm, T. Goebel, A. Dechene, A. Bellendorf, et al.,
Factors associated with contralateral liver hypertrophy after unilateral radio-
embolization for hepatocellular carcinoma, PloS One 12 (7) (2017) e0181488.
[65] X. Palard, J. Edeline, Y. Rolland, S. Le Sourd, M. Pracht, S. Laffont, et al., Dosimetric
parameters predicting contralateral liver hypertrophy after unilobar radio-
embolization of hepatocellular carcinoma, Eur. J. Nucl. Med. Mol. Imag. 45 (3)
(2018) 392–401.
[66] J.Y. Teo, J.C. Allen Jr., D.C. Ng, S.P. Choo, D.W. Tai, J.P. Chang, et al., A systematic
review of contralateral liver lobe hypertrophy after unilobar selective internal ra-
diation therapy with Y90, HPB 18 (1) (2016) 7–12.
[67] E. Birgin, E. Rasbach, S. Seyfried, N. Rathmann, S.J. Diehl, S.O. Schoenberg, et al.,
Contralateral liver hypertrophy and oncological outcome following radio-
embolization with (90)Y-microspheres: a systematic review, Cancers 12 (2) (2020).
[68] S. Hwang, S.G. Lee, G.Y. Ko, B.S. Kim, K.B. Sung, M.H. Kim, et al., Sequential
preoperative ipsilateral hepatic vein embolization after portal vein embolization to
induce further liver regeneration in patients with hepatobiliary malignancy, Ann.
Surg. 249 (4) (2009) 608–616.
[69] B. Guiu, F. Quenet, L. Escal, F. Bibeau, L. Piron, P. Rouanet, et al., Extended liver
venous deprivation before major hepatectomy induces marked and very rapid in-
crease in future liver remnant function, Eur. Radiol. 27 (8) (2017) 3343–3352.
[70] E. Deshayes, E. Schadde, L. Piron, F. Quenet, B. Guiu, Extended Liver Venous
Deprivation Leads to a Higher Increase in Liver Function that ALPPS in Early
Assessment : a comment to "Sparrelid, E. et al. Dynamic Evaluation of Liver Volume
and Function in Associating Liver Partition and Portal Vein Ligation for Staged
Hepatectomy. Journal of Gastrointestinal Surgery, J. Gastrointest. Surg. 21 (10)
(2017) 1754–1755 2017.
[71] X. Guo, G. Liu, X. Zhang, Meta-analysis of ischemic preconditioning (IP) on post-
operative outcomes after liver resections, Medicine (Baltim.) 96 (48) (2017) e8217.
[72] Y. Ushitora, H. Tashiro, S. Takahashi, H. Amano, A. Oshita, T. Kobayashi, et al.,
Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement
of liver function, Dig. Surg. 28 (1) (2011) 9–14.
[73] X. Lv, F. Yang, X. Guo, T. Yang, T. Zhou, X. Dong, et al., Hypersplenism is correlated
with increased risk of hepatocellular carcinoma in patients with post-hepatitis cir-
rhosis, Tumour Biol 37 (7) (2016) 8889–8900.
[74] Y. Nomura, M. Kage, T. Ogata, R. Kondou, H. Kinoshita, K. Ohshima, et al.,
Influence of splenectomy in patients with liver cirrhosis and hypersplenism,
Hepatol. Res. 44 (10) (2014) E100–E109.
[75] X. Liu, Z. Chen, M. Yu, W. Zhou, X. Zhi, T. Li, Safety of simultaneous hepatectomy
and splenectomy in the treatment of hepatocellular carcinoma complicated with
hypersplenism: a meta-analysis, Gastroenterol. Res. Pract. 2019 (2019) 9065845.
[76] M.J. Reiniers, P.B. Olthof, R.F. van Golen, M. Heger, A.A. van Beek, B. Meijer, et al.,
Hypothermic perfusion with retrograde outflow during right hepatectomy is safe
and feasible, Surgery 162 (1) (2017) 48–58.
[77] K. Imai, R. Adam, H. Baba, How to increase the resectability of initially unresectable
colorectal liver metastases: a surgical perspective, Ann Gastroenterol Surg 3 (5)
(2019) 476–486.
[78] L. Weinberg, L. Mackley, A. Ho, S. McGuigan, D. Ianno, M. Yii, et al., Impact of a
goal directed fluid therapy algorithm on postoperative morbidity in patients un-
dergoing open right hepatectomy: a single centre retrospective observational study,
BMC Anesthesiol. 19 (1) (2019) 135.
[79] S.T. Fan, C.M. Lo, E.C. Lai, K.M. Chu, C.L. Liu, J. Wong, Perioperative nutritional
support in patients undergoing hepatectomy for hepatocellular carcinoma, N. Engl.
J. Med. 331 (23) (1994) 1547–1552.
[80] A. Fujio, S. Miyagi, K. Tokodai, W. Nakanishi, R. Nishimura, K. Mitsui, et al., Effects
of a new perioperative enhanced recovery after surgery protocol in hepatectomy for
hepatocellular carcinoma, Surg. Today 50 (6) (2019) 615–622.
[81] V. Agarwal, J.V. Divatia, Enhanced recovery after surgery in liver resection: current
concepts and controversies, Korean J Anesthesiol. 72 (2) (2019) 119–129.
[82] P. Rouxel, H. Beloeil, Enhanced recovery after hepatectomy: a systematic review,
Anaesth. Crit. Care Pain Med. 38 (1) (2019) 29–34.
[83] W.H. She, A.C. Chan, T.T. Cheung, K.S. Chok, W.C. Dai, S.C. Chan, et al., Short- and
long-term impact of reoperation for complications after major hepatectomy for
hepatocellular carcinoma, Surgery 160 (5) (2016) 1236–1243.
[84] S. Kuboki, H. Shimizu, M. Ohtsuka, A. Kato, H. Yoshitomi, K. Furukawa, et al.,
Incidence, risk factors, and management options for portal vein thrombosis after
hepatectomy: a 14-year, single-center experience, Am. J. Surg. 210 (5) (2015)
878–885 e2.
[85] N. Kennoki, T. Saguchi, T. Sano, T. Moriya, N. Shirota, J. Otaka, et al., Successful
recanalization of acute extensive portal vein thrombosis by aspiration throm-
bectomy and thrombolysis via an operatively placed mesenteric catheter: a case
report, BJR Case Rep 4 (4) (2018) 20180024.
[86] R. Uflacker, Applications of percutaneous mechanical thrombectomy in transju-
gular intrahepatic portosystemic shunt and portal vein thrombosis, Tech. Vasc.
Intervent. Radiol. 6 (1) (2003) 59–69.
[87] L.T. Hoekstra, T.M. van Gulik, D.J. Gouma, O.R. Busch, Posthepatectomy bile
leakage: how to manage, Dig. Surg. 29 (1) (2012) 48–53.
[88] S. Bhattacharjya, J. Puleston, B.R. Davidson, J.S. Dooley, Outcome of early endo-
scopic biliary drainage in the management of bile leaks after hepatic resection,
Gastrointest. Endosc. 57 (4) (2003) 526–530.
[89] A. Dechene, C. Jochum, C. Fingas, A. Paul, D. Heider, W.K. Syn, et al., Endoscopic
management is the treatment of choice for bile leaks after liver resection,
Gastrointest. Endosc. 80 (4) (2014) 626–633 e1.
[90] M. Golriz, A. Majlesara, S. El Sakka, M. Ashrafi, J. Arwin, N. Fard, et al., Small for
Size and Flow (SFSF) syndrome: an alternative description for posthepatectomy
liver failure, Clin. Res. Hepatol. Gastroenterol. 40 (3) (2016) 267–275.
[91] N.N. Rahbari, O.J. Garden, R. Padbury, M. Brooke-Smith, M. Crawford, R. Adam,
et al., Posthepatectomy liver failure: a definition and grading by the international
study group of liver surgery (ISGLS), Surgery 149 (5) (2011) 713–724.
[92] Z.Q. Zhang, L. Xiong, J.J. Zhou, X.Y. Miao, Q.L. Li, Y. Wen, et al., Ability of the ALBI
grade to predict posthepatectomy liver failure and long-term survival after liver
resection for different BCLC stages of HCC, World J. Surg. Oncol. 16 (1) (2018) 208.
[93] J. Meyer, A. Balaphas, C. Combescure, P. Morel, C. Gonelle-Gispert, L. Buhler,
Systematic review and meta-analysis of thrombocytopenia as a predictor of post-
hepatectomy liver failure, HPB 21 (11) (2019) 1419–1426.
[94] A.M. Fagenson, E.M. Gleeson, H.A. Pitt, K.N. Lau, Albumin-bilirubin score vs model
for end-stage liver disease in predicting post-hepatectomy outcomes, J. Am. Coll.
Surg. 230 (4) (2020) 637–645.
[95] E. Sparrelid, S. Gilg, T.M. van Gulik, Systematic Review of MARS Treatment in Post-
hepatectomy Liver Failure, HPB, Oxford), 2020.
[96] S.C. Chan, W.W. Sharr, A.C. Chan, K.S. Chok, C.M. Lo, Rescue living-donor liver
transplantation for liver failure following hepatectomy for hepatocellular carci-
noma, Liver Cancer 2 (3–4) (2013) 332–337.
Albert Chan∗
Division of Hepatobiliary & Pancreatic Surgery, & Liver Transplantation,
Department of Surgery, The University of Hong Kong, & State Key




Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery,
National University of Singapore, Singapore
Taizo Hibi
Department of Pediatric Surgery and Transplantation, Kumamoto University
Graduate School of Medical Sciences, Japan
Fabrizio Di Benedetto
Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit,
University of Modena and Reggio Emilia, Modena, Italy
Alejandro Serrablo
Chairman of HPB Surgical Division. Miguel Servet University Hospital.
Zaragoza, Spain
∗ Corresponding author.
Perspective International Journal of Surgery xxx (xxxx) xxx–xxx
6
